| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer | Chief Medical Officer
1 company
Paul K. Audhya is Chief Medical Officer at KALV. From August 2022 to April 2026, the filings on record show 0 open-market purchases and 23 sales. Paul K. Audhya's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.8M at current prices.
Our model assigns Paul K. Audhya a below-average insider score of 44/100, based on 22 past trades. Over a 12-month horizon, 11.8% of those trades were profitable, with an average 12-month return of -38.1%.
The KALV filings lean toward selling, a net 103,890 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2023 | KALV Kalvista Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 3,412 | $7.66 | $26,135.92 | -26.7% | +28.1% | +83.0% | |
| Nov 18, 2022 | KALV Kalvista Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 722 | $5.44 | $3,927.68 | -10.8% | +49.7% | +59.5% | |
| Aug 17, 2022 | KALV Kalvista Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 725 | $14.96 | $10,847.09 | -30.0% | -65.7% | -28.1% |